Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Patients with resected mucosal (HNSCC) or cutaneous (cSCC) squamous carcinomas of the head and neck undergo adjuvant therapy based on clinicopathologic prognosticators. Most patients are overtreated or undertreated, with substantial morbidity from locoregional recurrences and locoregional therapies. It is unknown whether postoperative ctDNA molecular residual disease (MRD) testing could improve patient selection.
1. Introduction Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide with approximately 60,000 patients diagnosed annually in the United States [1]. While patients with human papilloma virus (HPV)-positive HNSCC tend to have an excellent prognosis [2], HPV-negative patients have an approximately 50% recurrence rate despite treatment with standard cisplatin-based chemoradiotherapy and/or surgery.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
